=> d l4
L4 HAS NO ANSWERS
L4 STR



VPA 7-1/2/3 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 3 8
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

=> d his l6

(FILE 'REGISTRY' ENTERED AT 09:25:47 ON 14 OCT 2008)
L6 190 S L4 FUL

=> d l1
L1 HAS NO ANSWERS
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 9 3
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

=> d his l2

(FILE 'REGISTRY' ENTERED AT 09:24:02 ON 14 OCT 2008)
L2 8 S L1

=> d his l7

(FILE 'REGISTRY' ENTERED AT 09:25:47 ON 14 OCT 2008)

```
L7          182 S L6 NOT L2

=> d his l8

     (FILE 'CAPLUS' ENTERED AT 09:27:31 ON 14 OCT 2008)
L8            2 S L7

=> d his l10

     (FILE 'CAPLUS' ENTERED AT 09:27:46 ON 14 OCT 2008)
L10           1 S L9

=> d his l11

     (FILE 'CAPLUS' ENTERED AT 09:27:46 ON 14 OCT 2008)
L11           1 S L8 NOT L10

     FILE 'STNGUIDE' ENTERED AT 09:28:45 ON 14 OCT 2008

     FILE 'REGISTRY' ENTERED AT 09:28:56 ON 14 OCT 2008

=> d bib abs hitstr l11
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y



L11  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2003:991510  CAPLUS
DN   140:42193
TI   Preparation of bicyclic pyrimidine derivatives as antiinflammatory agents
     for treatment of allergic diseases
IN   Arai, Hitoshi; Matsumura, Tsutomu; Ishida, Hiroshi; Yamaura, Yosuke;
     Aratake, Seiji; Ohshima, Etsuo; Yanagawa, Koji; Miyama, Motoki; Suzuki,
     Koji; Kawabe, Ari; Nakanishi, Satoshi; Kobayashi, Katsuya; Sato, Takashi;
     Miki, Ichiro; Ueno, Kimihisa; Fujii, Shinya; Iwase, Miho
PA   Kyowa Hakko Kogyo Co., Ltd., Japan
SO   PCT Int. Appl., 467 pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO 2003104230        A1    20031218    WO 2003-JP7200          20030606
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003242252         A1    20031222    AU 2003-242252          20030606
     EP 1552842            A1    20050713    EP 2003-733302          20030606
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     US 20070037834        A1    20070215    US 2005-516750          20050331
PRAI JP 2002-166504        A     20020607
```

WO 2003-JP7200 W 20030606
OS MARPAT 140:42193
GI



I

AB The title compds. I [wherein m and n = independently 1-3; R1 = (un)substituted amino; R2 = -B-(CX2)p-R7, (un)substituted piperidinyl, piperazinyl, or amino; B = O CH=CH, C.tplbond.C, or phenylene; p = 1-4; X = H, halo, or (un)substituted alkyl; R7 = (un)substituted amino; A = a single bond, CO, SO2, OCO, OCS, SCO, SCS, (un)substituted NHCO, NHCS, or amino; R3 = H, (un)substituted alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl, etc.] or quaternary ammonium salts, or pharmaceutically acceptable salts thereof are prepared I have an antiinflammatory effect and an effect of controlling the function(s) of TARC and/or MDC and, therefore, are usable in treating and/or preventing various diseases in which T cells participate, for example, allergic diseases, autoimmune diseases, rejection at transplantation, etc. (no data). Formulations containing I as an active ingredient were also described.

IT 635693-82-2P 635693-84-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of bicyclic pyrimidine derivs. as antiinflammatory agents for treatment of allergic diseases)

RN 635693-82-2 CAPLUS
CN Methanone, cyclopropyl[4-[[(2,4-dichlorophenyl)methyl]amino]-7,8-dihydro-2-[4-[(1-methyl-4-piperidinyl)oxy]-1-piperidinyl]pyrido[4,3-d]pyrimidin-6(5H)-yl]- (CA INDEX NAME)



RN 635693-84-4 CAPLUS
CN Pyrido[4,3-d]pyrimidine-6(5H)-carboxamide, 4-[[(2,4-dichlorophenyl)methyl]amino]-N-ethyl-7,8-dihydro-2-[4-[(1-methyl-

4-piperidinyl)oxy]-1-piperidinyl]- (CA INDEX NAME)



RE.CNT 16   THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT